Two-year outcomes after first-or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention …
Objectives: This study sought to assess device-specific outcomes after implantation of bare-
metal stents (BMS), zotarolimus-eluting Endeavor Sprint stents (ZES-S), paclitaxel-eluting …
metal stents (BMS), zotarolimus-eluting Endeavor Sprint stents (ZES-S), paclitaxel-eluting …
Randomized comparison of 6-versus 24-month clopidogrel therapy after balancing anti-intimal hyperplasia stent potency in all-comer patients undergoing …
M Valgimigli, G Campo, G Percoco, M Monti… - American Heart …, 2010 - Elsevier
BACKGROUND: The optimal duration of clopidogrel therapy after coronary stenting is
debated because of the scarcity of randomized controlled trials and inconsistencies arising …
debated because of the scarcity of randomized controlled trials and inconsistencies arising …
Two-year clinical outcome of all-comers treated with three highly dissimilar contemporary coronary drug-eluting stents in the randomised BIO-RESORT trial
MM Kok, RA Buiten, PW Danse… - …, 2018 - research.utwente.nl
Aims: The aim of the study was to evaluate the two-year clinical outcome of all-comer trial
participants who were treated with two very different thin-strut biodegradable polymer versus …
participants who were treated with two very different thin-strut biodegradable polymer versus …
Should duration of dual antiplatelet therapy depend on the type and/or potency of implanted stent? A pre-specified analysis from the PROlonging Dual antiplatelet …
Aims The purpose of this pre-specified analysis of the PROlonging Dual antiplatelet
treatment after Grading stent-induced Intimal hyperplasia studY (PRODIGY) was to assess …
treatment after Grading stent-induced Intimal hyperplasia studY (PRODIGY) was to assess …
Third-generation zotarolimus-eluting and everolimus-eluting stents in all-comer patients requiring a percutaneous coronary intervention (DUTCH PEERS): a …
C von Birgelen, H Sen, MK Lam, PW Danse… - The Lancet, 2014 - thelancet.com
Background Third-generation, permanent-polymer-based drug-eluting stents with novel,
flexible designs might be more easily delivered than previous generations of stents in …
flexible designs might be more easily delivered than previous generations of stents in …
Incidence and predictors of very late (≥ 4 years) major cardiac adverse events in the DESIRE (Drug-Eluting Stents in the Real World)-Late registry
JR Costa, A Sousa, AC Moreira, RA Costa… - JACC: Cardiovascular …, 2010 - jacc.org
Objectives: Our aim was to access the incidence of late major adverse cardiac events
(MACE) and stent thrombosis (ST) in nonselected, complex patients followed for a period≥ …
(MACE) and stent thrombosis (ST) in nonselected, complex patients followed for a period≥ …
Unrestricted randomised use of two new generation drug-eluting coronary stents: 2-year patient-related versus stent-related outcomes from the RESOLUTE All …
S Silber, S Windecker, P Vranckx, PW Serruys - The Lancet, 2011 - thelancet.com
Summary Background In the RESOLUTE All Comers trial, the Resolute zotarolimus-eluting
stent was non-inferior to the Xience V everolimus-eluting stent for the primary stent-related …
stent was non-inferior to the Xience V everolimus-eluting stent for the primary stent-related …
Thin, very thin, or ultrathin strut biodegradable or durable polymer-coated drug-eluting stents: 3-year outcomes of BIO-RESORT
RA Buiten, EH Ploumen, P Zocca, CJM Doggen… - JACC: Cardiovascular …, 2019 - jacc.org
Objectives: The aim of this study was to assess the 3-year safety and efficacy of treating all-
comer patients with 3 contemporary drug-eluting stents (DES). Background: The BIO …
comer patients with 3 contemporary drug-eluting stents (DES). Background: The BIO …
Safety and efficacy of new-generation drug-eluting stents in women undergoing complex percutaneous coronary artery revascularization: from the WIN-DES …
Objectives: The purpose of this study was to investigate the safety and efficacy of new-
generation drug-eluting stents (DES) versus early-generation DES in women undergoing …
generation drug-eluting stents (DES) versus early-generation DES in women undergoing …
Impact of sex on 3-year outcome after percutaneous coronary intervention using bare-metal and drug-eluting stents in previously untreated coronary artery disease …
Y Onuma, N Kukreja, J Daemen… - JACC: Cardiovascular …, 2009 - jacc.org
Objectives: We investigated the impact of sex on outcomes after percutaneous coronary
intervention (PCI) with drug-eluting stent (DES). Background: Women have a higher risk of …
intervention (PCI) with drug-eluting stent (DES). Background: Women have a higher risk of …